Skip to content

DE · 4XT.DE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

XPhyto Therapeutics Corp. (4XT.DE) intrinsic value and stock valuation

$0.37as of 2026-11-21 · Mkt cap 0

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

XPhyto Therapeutics Corp. DCF and intrinsic value

InvestorsCraft values 4XT.DE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 4XT.DE’s statements →

XPhyto Therapeutics Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Vancouver, BC V6J 3B1 xphyto.com

How the business is doing

Fiscal 2018–2021, USD

Revenue
$290K
20182021
Net income
-$-20.64M
20182021
Free cash flow
-$-12.61M
20182021
Total equity
$1.67M
20182021

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2018–2021, USD
2021202020192018
Revenue$290K$350K$210K$0.00
Operating income-$-20.02M-$-14.8M-$-7.12M-$-870K
Net income-$-20.64M-$-16.89M-$-7.67M-$-860K
EPSd-$-265.47K-$-295.18K-$-169.5K-$-17.67K
Operating cash flow-$-12.16M-$-10.2M-$-3.69M-$-620K
Capital expenditure-$-450K-$-160K-$-120K-$-40K
Free cash flow-$-12.61M-$-10.36M-$-3.81M-$-660K
Total assets$9.73M$8.28M$8.66M$8.93M
Total debt$5.46M$3.31M$1.4M$780K
Net debt$4.1M$730K$1.1M-$-1.58M
Total equity$1.67M$4.01M$6.32M$7.76M
Cash and short-term investments$1.35M$2.58M$300K$2.37M
Income statement
2021202020192018
Revenue$290K$350K$210K$0.00
Cost of revenue$90K$0.00$0.00$0.00
Gross profit$200K$350K$210K$0.00
Research and development expenses$3.34M$3.24M$270K$0.00
Selling, general and administrative expenses$12.4M$11M$6.11M$770K
Other expenses$800K$900K$950K$100K
Operating expenses$16.5M$15.2M$7.32M$870K
Cost and expenses$16.6M$15.2M$7.32M$870K
Interest income$0.00$0.00$0.00$0.00
Interest expense$730K$300K$110K$10K
Depreciation and amortization$820K$900K$950K$100K
Ebitda-$-19.19M-$-16.05M-$-6.66M-$-760K
Operating income-$-20.02M-$-14.8M-$-7.12M-$-870K
Total other income/expenses, net-$-730K-$-2.44M-$-600K$10K
Income before tax-$-20.75M-$-17.25M-$-7.71M-$-860K
Income tax expense-$-110K-$-360K-$-50K$0.00
Net income-$-20.64M-$-16.89M-$-7.67M-$-860K
Weighted average shares outstanding$77.8M$57.2M$45.3M$48.7M
Weighted average diluted shares outstanding$77.8M$57.2M$45.3M$48.7M
Balance sheet
2021202020192018
Cash and short-term investments$1.35M$2.58M$300K$2.37M
Net receivables$550K$310K$290K$100K
Inventory$740K$0.00$0.00$0.00
Total current assets$2.7M$3.03M$710K$2.47M
Property, plant and equipment, net$1.13M$5.24M$5.92M$5.27M
Goodwill and intangible assets$5.89M$10K$2.02M$650K
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$7.02M$5.25M$7.94M$6.46M
Total assets$9.73M$8.28M$8.66M$8.93M
Accounts payable$520K$570K$260K$120K
Short-term debt$3.13M$500K$610K$70K
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$5.45M$1.47M$1.38M$460K
Long-term debt$2.33M$2.81M$790K$710K
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$2.61M$2.81M$950K$710K
Capital lease obligations$0.00$0.00$0.00$0.00
Total liabilities$8.06M$4.28M$2.33M$1.17M
Common stock$39.4M$24.6M$12.3M$6.59M
Retained earnings-$-43.38M-$-24.93M-$-8.53M-$-870K
Accumulated other comprehensive income (loss)$5.53M$4.08M$2.56M$260K
Total equity$1.67M$4.01M$6.32M$7.76M
Total investments$0.00$0.00$0.00$0.00
Total debt$5.46M$3.31M$1.4M$780K
Net debt$4.1M$730K$1.1M-$-1.58M
Cash flow statement
2021202020192018
Net income-$-20.64M-$-16.89M-$-7.67M-$-860K
Depreciation and amortization$820K$900K$950K$100K
Stock-based compensation$3.28M$2.59M$1.77M$10K
Change in working capital-$-420K$30K$180K$130K
Accounts receivable$0.00$0.00$0.00$0.00
Inventory-$-740K$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-12.16M-$-10.2M-$-3.69M-$-620K
Investments in property, plant and equipment-$-450K-$-160K-$-120K-$-40K
Acquisitions, net-$-4.86M$0.00-$-340K-$-990K
Net cash used for investing activities-$-5.31M-$-160K-$-460K-$-1.57M
Common stock issued$7.35M$0.00$810K$3.18M
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$16.2M$12.7M$2.08M$4.56M
Net change in cash-$-1.23M$2.29M-$-2.07M$4.56M
Cash at end of period$1.35M$2.58M$300K$2.37M
Operating cash flow-$-12.16M-$-10.2M-$-3.69M-$-620K
Capital expenditure-$-450K-$-160K-$-120K-$-40K
Free cash flow-$-12.61M-$-10.36M-$-3.81M-$-660K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About XPhyto Therapeutics Corp.

        XPhyto Therapeutics Corp. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

        CEO
        Hugh A. D. Rogers
        Employees
        0
        Beta
        0.15

        Explore

        Frequently asked questions

        What is the intrinsic value of XPhyto Therapeutics Corp. (4XT.DE)?

        InvestorsCraft does not currently publish an intrinsic value for 4XT.DE. How the IC value is calculated.

        Is 4XT.DE undervalued?

        InvestorsCraft does not publish an undervaluation signal for 4XT.DE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.